These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 22674145)

  • 1. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection.
    Loupy A; Lefaucheur C; Vernerey D; Chang J; Hidalgo LG; Beuscart T; Verine J; Aubert O; Dubleumortier S; Duong van Huyen JP; Jouven X; Glotz D; Legendre C; Halloran PF
    J Am Soc Nephrol; 2014 Oct; 25(10):2267-77. PubMed ID: 24700874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses.
    Rouzier R; Pronzato P; Chéreau E; Carlson J; Hunt B; Valentine WJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):621-37. PubMed ID: 23722312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. To (genetic) test or not to test, that is the question.
    Mushlin AI
    J Comp Eff Res; 2015 Sep; 4(5):429-31. PubMed ID: 26388528
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer.
    Chen E; Tong KB; Malin JL
    Am J Manag Care; 2010 Dec; 16(12):e333-42. PubMed ID: 21291290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
    Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
    PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer breakthrough in gene profilings?
    Bateman C
    S Afr Med J; 2009 Nov; 99(11):780-2. PubMed ID: 20218471
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Reed SD; Lyman GH
    Cancer; 2012 Dec; 118(24):6298-9; author reply 6299-300. PubMed ID: 22674145
    [No Abstract]   [Full Text] [Related]  

  • 9. Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?
    Lamond NW; Skedgel C; Younis T
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):243-50. PubMed ID: 23570435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing therapeutically developed assays.
    Kolesar JM
    Manag Care; 2008 Jul; 17(7 Suppl 7):9-12; discussion 17-8. PubMed ID: 19097282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
    Markopoulos C
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):179-94. PubMed ID: 23406559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.
    Ethier JL; Amir E
    Mol Diagn Ther; 2016 Aug; 20(4):307-13. PubMed ID: 27235162
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.